HC Wainwright Reaffirms “Buy” Rating for TAIWAN LIPOSOME/S (NASDAQ:TLC)

HC Wainwright reissued their buy rating on shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) in a research report report published on Thursday morning, AnalystRatings.com reports. The firm currently has a $11.00 target price on the stock.

A number of other analysts also recently weighed in on TLC. Cantor Fitzgerald cut their target price on TAIWAN LIPOSOME/S from $11.00 to $10.00 and set an overweight rating for the company in a research report on Wednesday. Zacks Investment Research downgraded TAIWAN LIPOSOME/S from a buy rating to a hold rating in a research report on Wednesday, January 29th. Finally, ValuEngine upgraded TAIWAN LIPOSOME/S from a hold rating to a buy rating in a research report on Tuesday, December 31st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. TAIWAN LIPOSOME/S has a consensus rating of Buy and a consensus price target of $9.00.

Shares of NASDAQ:TLC traded up $0.17 during trading on Thursday, reaching $5.40. 732 shares of the company traded hands, compared to its average volume of 1,788. The company’s 50 day moving average is $5.38 and its two-hundred day moving average is $5.23. The firm has a market capitalization of $200.24 million, a PE ratio of -9.64 and a beta of 0.78. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.14. TAIWAN LIPOSOME/S has a 52 week low of $4.61 and a 52 week high of $8.54.

A hedge fund recently raised its stake in TAIWAN LIPOSOME/S stock. Millennium Management LLC increased its holdings in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) by 564.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 92,915 shares of the company’s stock after buying an additional 112,915 shares during the quarter. Millennium Management LLC owned 0.29% of TAIWAN LIPOSOME/S worth $474,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.11% of the company’s stock.


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Story: Monthly Dividend Stocks

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.